Recombinant hepatitis B vaccination in renal failure patients

Current Pharmaceutical Biotechnology

Volumn 4, Issue 2, 2003, Pages 141-151

  Vlassopoulos, D ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

Haemodialysis; Hepatitis B; Immune deficiency; Renal failure; Vaccination

Indexed keywords

ADJUVANT; ALPHA INTERFERON; CD86 ANTIGEN; CYCLOSPORIN; DIPHTHERIA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; LEVAMISOLE; MONOKINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; THYMOPENTIN;

ALLELE; ANEMIA; BACTERIAL INFECTION; BIOCOMPATIBILITY; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CHRONICITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; GENE EXPRESSION; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERPARATHYROIDISM; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION PREVENTION; IRON OVERLOAD; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CARCINOMA; LIVER CIRRHOSIS; MALNUTRITION; METHODOLOGY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; REVIEW; RISK ASSESSMENT; SEROCONVERSION; SURVIVAL RATE; T LYMPHOCYTE; UREMIA;

HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE; PATIENTS; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); HEPATITIS B VIRUS;

EID: 0037388296     PISSN: 13892010     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389201033489900     Document Type: Review

References (73)

1. Rapicetta, M. (1992) Hepatitis B vaccination in dialysis centers: advantages and limits. Nephron, 61, 284-286.
2. Descamps-Latscha, B. and Chatenoud, L. (1996) T cells and B cells in chronic renal failure. Semin. Nephrol., 16(3), 183-191.
3. Girndt, M.; Kohler, H.; Schiedhelm-Weick, E.; Schlaak, J. F.; Meyer Zum Buschenfelde, K. -H. and Fleischer, B. (1995) Production of interleukin-6, tumor necrosis factor α and interieukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int., 47, 559-565.
4. Girndt, M.; Sester, M.; Sester, U.; Kaul, H and Kohler, H. (2001) Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int., 59, 1382-1389.
5. Peces, R.; de la Torre, M.; Alcazar, R. and Urra, J.M. (1997) Prospective analysis of the factors influencing the antibody response to Hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis., 29(2), 239-245.
6. Haubitz, M.; Ehlerding, G.; Beigel, A.; Heuer, U.; Hemmerling, A.E. and Thoma, H.A. (1996) Clinical experience with a new recombinant hepatitis B vaccine in previous non-responders with chronic renal insufficiency. Clin. Nephrol., 45(3), 180-182.
7. Girndt, M.; Sester, U.; Sester, M.; Deman, E.; Kaul, H. and Kohler, H. (2001) The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int., 60, 2385-2391.
8. Van Riemsdijk-van Overbeeke, I.C.; Baan, C.C.; Knoop, C.J.; Loonen, E.H.M.; Zietse, R. and Weimar, W. (2001) Quantitative flow cytometry shows activation of TNF-α system but not of the IL-2 system at the single cell level in renal replacement therapy. Nephrol. Dial. Transplant., 16, 1430-1435.
9. Stachowski, J.; Pollok, M.; Barth, C.; Maciejewski, J. and Baldamus, C. A. (1994) Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol. Dial. Transplant., 9, 144-152.
10. Katkow, W.N. and Dienstag, J.L. (1991) Prevention and therapy of viral hepatitis. Semin. Liver Dis., 11(2), 165-174.
11. Vlassopoulos, D.; Magana, P.; Hadjiyannakos, D.; Spyropoulou, M.; Lilis, D.; Stavropoulou, C. and Hadjiconstantinou, V. (1998) Factors involved in low response to HBV vaccine in health and end-stage renal failure. Nephrol. Dial. Transplant., 13, A 191.
12. Pol, S.; Legendre, C.; Mattlinger, B.; Berthelot, P. and Kreis, H. (1990) Genetic basis to hepatitis B vaccine in hemodialyzed patients. J Hepatol., 11, 385-387.
13. Vlassopoulos, D.; Arvanitis, D.; Lilis, D.; Louizou, K. and Hadjiconstantinou, V. (1999) Hepatitis B vaccination in ESRD. 8 year follow up. Factors involved in the immune response. Nephrol. Dial. Transplant., 14, A 114.
14. Caillat-Zucman, S.; Gimenez, J.-J.; Wambergue, F.; Albouze, G.; Lebkiri, B.; Naret, C.; Moynot, A.; Jungers, P. and Bach, J.-F. (1998) Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int., 53, 1626-1630.
15. Kruskall, M.S.; Alper, C.A.; Awdeh, Z.; Yunis, E.J. and Marcus-Bagley, D. (1992) The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med., 175, 495-502.
16. Rahman, F.; Dahmen, A.; Herzog-Hauff, S.; Bocher, W.O.; Galle, P.R. and Lohr, H.F. (2000) Cellular and humoral responses induced by intradermal or intramuscular vaccination with the major Hepatitis B surface antigen. Hepatology, 31, 521-527.
17. Vanholder, R.; Van Loo, A.; Dhondt, A.M.: De Smet, R. and Ringoir, S. (1996) Influence of uremia and haemodialysis on host defense and infection. Nephrol. Dial. Transplant., 11, 593-598.
18. Gaciong, Z.; Alexiewicz, J.M. and, Massry, S.G. (1991) Impaired in vivo antibody production in CRF rats: Role of secondary hyperparathyroidism. Kidney Int., 40, 862-867.
19. Fernandez, E.; Betriu, M.A.; Gomez, R. and Montoliu, J. (1996) Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol. Dial. Transplant., 11, 1559-1563.
20. Fivush, B.A. and Neu, A.M. (1998) Immunization guidelines for pediatric renal diseases. Seminars in Nephrology, 18(3), 256-263.
21. Fabrizi, F.; Andrulli, S.; Bacchini, G.; Corti, M. and Locatelli, F. (1997) Intradermal versus intramuscular hepatitis B vaccination in non-responding chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol. Dial. Transplant., 12, 1204-1211.
22. Navarro, J.F.; Teruel, J.L.; Mateos, M. and Ortuno, J. (1994) Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in haemodialysis patients. Clin. Nephrol., 41(22),113-116.
23. Navarro, J.F.; Teruel, J.L.; Mateos, M.; Marcen, R. and Ortuno, J. (1996) Antibody level after hepatitis B vaccination in haemodialysis patients: influence of hepatitis C virus infection. Am. J Nephrol., 16, 95-97.
24. Guerin, A.; Buisson, Y.; Nutini, M.T.; Saliou, P.; London, G. and Marchais, S. (1992) Response to vaccination against tetanus in chronic haemodialyzed patients. Nephrol. Dial. Transplant., 7, 323-326.
25. Girndt, M.; Pietsch, M. and Kohler, H. (1995) Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am. J. Kidney Dis., 26(3), 454-460.
26. Jungers, P. (1998) Vaccination contre l'hépatite B dans les centres d'hémodialyse. Nephrologie, 19, 37-38.
27. Buti, M.; Viladomiu, L.; Jardi, R.; Olmos, A.; Rodriguez, J.A.; Bartolome, J.; Esteban, R. and Guardia, J. (1992) Long-term immunogenicity and efficacy of hepatitis B vaccine in haemodialysis patients. Am. J. Nephrol., 12, 144-147.
28. Kreft, B.; Klouche, M.; Kreft, R.; Kirchner, H. and Sack, K. (1997) Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. Kidney Int., 52, 212-216.
29. Shinefield, H.; Black, S.; Fattom, A. and Horwith, G. (2002) Use of a Staphylococcus aureus conjugate vaccine in patients receiving haemodialysis. N. Engl. J. Med., 346(7), 491-496.
30. Sever, M.S.; Yildiz, A.; Eraksoy, H.; Badur, S. Yuksel-Onel, D.; Gorcin, B., Turk, S. and Erkoc, R. (1999) Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Nephron, 81, 55-59.
31. Stark, K.; Gunther, M.; Schonfeld, C. and Tullius. S.G. (2002) Immunizations in solid-organ transplant recipients. Lancet, 359, 957-965.
32. Kruger, S.; Seyfarth, M.: Sack, K. and Kreft, B. (1999) Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Vaccine, 17, 1145-1150.
33. Lefebure, A.F.; Verpooten, G.A.; Couttenye, M.M. and DeBroe, M.E. (1993) Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine, 11(4), 397-399.
34. Miller, E.R.; Alter, M.J. and Tokars, J.I. (1999) Protective effect of hepatitis B vaccine in chronic haemodialysis patients. Am. J. Kidney, 33(2), 356-360.
35. Lewis-Ximenez, L.L.; Oliveira, J.M.; Mercadante, L.A.C.; De Castro, L.; Santa Catharina, W.; Stuver, S. and Yoshida, C.F.T. (2001) Serological and vaccination profile of haemodialysis patients during an outbreak of hepatitis B virus infection. Nephron, 87, 19-26.
36. Jibani, M.M.; Heptonstall, J.; Walker, A.M.; Bloodworth, L.O. and Howard, A.J. (1994) Hepatitis B immunization in UK renal units: failure to put policy into practice. Nephrol. Dial. Transplant., 9, 1765-1768.
37. Kohler, H. (1994) Hepatitis B immunization in dialysis patients-is it worthwhile? Nephrol. Dial. Transplant., 9, 1719-1720.
38. Crosnier, J.; Jungers, P.; Courouce, A.M.; Laplanche, A.; Benhamou, E.; Degos, F.; Lacour, B.; Prunet, P.; Cerisier, Y. and Guesry, P. (1981) Randomized placebo- controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients. Lancet, 1(8224), 797-800.
39. Stevens, C.E.; Alter, H.J.; Taylor, P.E.; Zhang, E.A.; Harley, E.J.; Szmuness, W. and the Dialysis Vaccine Trial Study Group. (1984) Hepatitis B vaccine in patients receiving haemodialysis. Immunogenicity and efficacy. N. Engl. J. Med., 311, 496-501.
40. Propst, T.; Propst, A.; Lhotta, K.; Vogel, W. and Konig, P. (1998) Reinforced intradermal Hepatitis B vaccination in haemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Amer. J. Kidney Dis., 32(6), 1041-1045.
41. Peces, R. and Laures, A.S. (2001) Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron, 89, 172-176.
42. Drachman, R.; Isacsohn, M.; Rudensky, B. and Drukker, A. (1989) Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol. Dial. Transplant., 4, 372-374.
43. Chang, P.C.; Schrander-van der Meer, A.M.; van Dorp, W.T. and van Leer, E. (1996) Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol. Dial. Transplant., 11, 191-193.
44. Szmuness, W.; Stevens, C.E.; Harley, E.J.; Zang, E.A.; Alter, H.J.; Taylor, P.E.; De Vera, A.; Chen, G.T.S.; Kellner, A. (1982) and Dialysis Vaccine Trial Study Group. N. Engl. J. Med., 307, 1481-1486.
45. Dukes, C.S.; Street, A.C.; Starling, J.F. and Hamilton, J.D. (1993) Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vaccine, 11(12), 1229-1232.
46. SAg. Lancet, ii, 1522-1523.
47. Kohler, H.; Arnold, W.; Renschin, G.; Dormeyer, H. -H. and Meyer Zum Buschenfelde, K.-H. (1984) Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int., 25, 124-128.
48. Zucherman, A.J. (1987) Appraisal of intradermal immunization against hepatitis B. Lancet, i, 435-436.
49. Mettang, T.; Schenk, U.; Thomas, S.; Machleidt, C.; Kiefer, T.; Fischer, F. -P. and Kuhlmannn, U. (1996) Nephron, 72, 192-196.
50. Mitwalli, A. (1996) Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron, 73, 417-420.
51. Carletti, P.; Bibiano, L.; Boggi, R.; Bordoni, E.; Ricciatti, A.M.; Della Bella, S.; Pauri, P.; Salvoni, G. and Mioli, V.A. (1992) HBV infection in haemodialysis patients: monitoring and prevention. Nephron, 61, 269-270.
52. Poux, J.M.; Ranger, S.; Lagarde, C.; Benevent, D.; Denis, F. and Leroux-Robert, C. (1994) Efficacy of intradermal injection of recombinant hepatitis B vaccine in dialysis patients. Nephrol. Dial. Transplant., 9, 1213-1214.
53. Ono, K. and Kashiwagi, S. (1991) Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B Vaccine in haemodialysis patients. Nephron, 58, 47-51.
54. Mauri, J.M.; Valles, M. (1997) and the collaborative group of Girona. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Nephrol. Dial. Transplant., 12, 729-732.
55. Bruguera, M.; Cremades, M.; Rodicio, J.; Alcazar, J.M.; Oliver, A.; Del Rio, G. and Esteban-Mur, R. (1989) Immunogenicity of a yeast-derived hepatitis B vaccine in haemodialysis patients. Am. J. Med., 87(suppl. 3A), 30S-32S.
56. Zuckerman, J.N.; Sabin, C.; Craig, F.M.; Williams, A. and Zuckerman, A.J. (1997) Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomized double blind dose-response study. BMJ, 314, 329-333.
57. Marangi, A.L.; Giordano, R.; Montanaro, A.; De Padova, F.; Schiavone, M.G.; Dongiovani, G. and Basile, C. (1994) Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two- step integrated protocol of vaccination. Amer. J. Kidney Dis., 23, 537-542.
58. Charest, A.F.; McDougall, J. and Goldstein, M.B. (2000) A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic haemodialysis patients. Am. J. Kidney Dis., 36(5), 976-982.
59. Evans, T.G., Schiff, M.; Graves. B.; Agosti J.; Barritt, M. L.; Garner, D. and Holley, J.L. (2000) The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic haemodialysis patients who have failed primary vaccination. Clin. Nephrol., 54(2), 138-142.
60. Brodersen, H.P.; Holtkamp, W.; Larbig, D.; Beckers, B.; Thiery, J.; Lautenschlager, J.; Probst, H. -J.; Ropertz, S. and Yavari, A. (1995) Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: a multicenter study. Nephrol. Dial. Transplant., 10, 1780-1783.
61. Hibberd, P.L. and Rubin, R.H. (1989) Immunization strategies for the Immunocompromised Host: The Need for Immunoadjuvants. Ann. Intern. Med., 110(12), 955-956.
62. Ayli, M.D.; Ensari, C.; Ayli, M.; Mandiroglu, F. and Mut, S. (2000) Effect of oral Levamisol supplementation to Hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients. Nephron, 84, 291-292.
63. Anandh, U.; Bastani, B. and Ballal, S. (2000) Granulocyte-Macrophage Colony-Stimulating Factor as an adjuvant to Hepatitis B vaccination in maintenance haemodialysis patients. Am. J. Nephrol., 20, 53-56.
64. Sennesael, J.J.; Van Der Niepen, P. and Verbeelen, D. L. (1991) Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int., 40, 121-128.
65. Vlassopoulos, D.; Arvanitis, D.; Lilis, D.; Katopodis, K.; Louizou, K. and Hadjiconstantinou, V. (1994) Low repeated doses of intradermal hepatitis B vaccine produce protective levels of antibodies in haemodialysis patients, non responding to usual and double multiple doses. J. Nephrol., 7(6), 340-341.
66. Arvanitis, D.; Vlassopoulos, D.; Lilis, D.; Dardioti, V.; Noussias, C.; Magana, P.; Louizou, K. and Hadjiconstantinou, V. (1996) Long term protection of haemodialysis patients from HBV, following response to conventional vaccination. Nephrol. Dial. Transplant., 11, A 182.
67. Gesemann, M. and Scheiermann, N. (1995) Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine, 13(5), 443-447.
68. Vlassopoulos, D.; Arvanitis, D.; Lilis, D.; Hadjiyannakos, D.; Louizou, K. and Hadjiconstantinou, V. (1997) Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and haemodialysis patients. Renal Failure, 19(3), 455-460.
69. Miller, K.; Gibbs, R.; Mulligan, M.; Nutman, T. and Francis, D. (1983) Intradermal hepatitis B virus vaccine: immunogenicity and side effects in adults. Lancet, ii, 1454-1456.
70. Vlassopoulos, D.; Arvanitis, D.; Lilis, D.; Louizou, K. and Hadjiconstantinou, V. (1999) Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in haemodialysis patients. Int. J. Artif. Org., 22(11), 739-743.
71. Birmingham, D.J.; Shen, X.P.; Hartman, J.A.; Dillon, J.J. and Hebert, L.A. (1996) Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic haemodialysis patients. Kidney Int., 50, 543-549.
72. Vlassopoulos, D.; Arvanitis; D.; Lilis, D., Noussias, C.; Magana, P.; Logothetis, E.; Katopodis, K. and Hadjiconstantinou, V. (1995) Intradermal vaccination against hepatitis B; full response of chronic renal failure and haemodialysis patients., Nephrol. Dial. Transplant., 10, 991.
73. Coursaget, P.; Yvonnet, B.: Gilks, W.R.; Wang, C.C.; Day, N.E.; Chiron, J. -P. and Diop-Mar, I. (1991) Scheduling of revaccination against hepatitis B virus. Lancet, 337, 1180-1183.